ISPOR - Budget Impact Analysis of Dasatinib as a Second-Line Therapy in Patients with Chronic Myelogenous Leukemia (Cml) in the Russian Federation

Full Text

Budget Impact Analysis of Dasatinib as a Second-Line Therapy in Patients with Chronic Myelogenous Leukemia (Cml) in the Russian Federation

Abstract

Authors

A Kulikov R Yagudina MV Protsenko

Back to Volume 18, Issue 7

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now